Oculis Secures EMA PRIME Designation for Neuroprotective Candidate Privosegtor
Event summary
- Oculis' Privosegtor received PRIME designation from the EMA for treating optic neuritis, following FDA's Breakthrough Therapy designation in January 2026.
- Phase 2 ACUITY trial data showed substantial improvements in low-contrast visual acuity and neuroprotective benefits.
- PIONEER registrational program, including trials for optic neuritis and NAION, is underway with PIONEER-1 initiated in Q4 2025.
- Privosegtor has Orphan Drug status from both EMA and FDA, highlighting its potential in addressing unmet medical needs.
The big picture
Oculis' PRIME designation for Privosegtor underscores the growing regulatory support for neuroprotective therapies in rare neuro-ophthalmic diseases. The strategic alignment with both EMA and FDA designations positions Privosegtor as a potential first-in-class treatment, addressing a significant unmet need in optic neuritis and related conditions. The PIONEER program's global development strategy could further solidify Oculis' leadership in neuro-ophthalmology.
What we're watching
- Regulatory Momentum
- Whether the dual PRIME and Breakthrough Therapy designations will accelerate Privosegtor's path to market and reduce development timelines.
- Clinical Execution
- The pace at which the PIONEER registrational trials progress and deliver pivotal data for optic neuritis and NAION.
- Market Potential
- How Privosegtor's potential as a first-in-class neuroprotective therapy could unlock a $7 billion market opportunity in the U.S. alone.